

12 November 2025

Sydney, Australia

## Nyrada Annual General Meeting Results

---

**Nyrada Inc (ASX:NYR)**, a clinical-stage biotechnology company developing Transient Receptor Potential Canonical (TRPC) ion channel inhibitors to treat a range of medical conditions, announces the results of today's Annual General Meeting.

***All resolutions were passed and decided by way of a poll.***

The results are set out in the attached document, in accordance with ASX Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act.

– ENDS –

### About Nyrada Inc.

Nyrada Inc. is a clinical-stage biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company's lead candidate, Xolatryp™, has shown efficacy in both cardioprotection and neuroprotection, and has just completed a first-in-human Phase I clinical trial. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, US, with limited liability for its stockholders.

[www.nyrada.com](http://www.nyrada.com)

*Authorised by John Moore, Non-Executive Chair, on behalf of the Board.*

#### Investor & Media Enquiries:

Dimitri Burshtein

T: 0491 789 391

E: [info@nyrada.com](mailto:info@nyrada.com)

#### Company Secretary:

David Franks

T: 02 8072 1400

E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)



### Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.

# Disclosure of Proxy Votes

Nyrada Inc

Annual General Meeting

Wednesday, 12 November 2025



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E [hello@automic.com.au](mailto:hello@automic.com.au)

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)			Results
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Re-election of Mr. John Moore as Director	P	104,170,052	102,670,096 98.56%	0 0.00%	7,102,756	1,499,956 1.44%	104,960,052 100.00%	0 0.00%	7,102,756	Carried
2 Re-election of Mr. Christopher Cox as Director	P	110,558,405	109,058,449 98.64%	0 0.00%	714,403	1,499,956 1.36%	111,348,405 100.00%	0 0.00%	714,403	Carried
3 Re-election of Dr. Ian Dixon as Director	P	103,656,943	102,023,653 98.42%	0 0.00%	7,615,865	1,633,290 1.58%	104,446,943 100.00%	0 0.00%	7,615,865	Carried
4 Re-election of Mr. Marcus Frampton as Director	P	108,791,068	107,291,112 98.62%	0 0.00%	2,481,740	1,499,956 1.38%	109,581,068 100.00%	0 0.00%	2,481,740	Carried
5 Re-election of Dr. Rüdiger Weseloh as Director	P	110,459,476	108,959,520 98.64%	0 0.00%	813,332	1,499,956 1.36%	111,249,476 100.00%	0 0.00%	813,332	Carried
6 Election of Mr. James Bonnar as Director	P	111,161,445	109,656,489 98.65%	0 0.00%	111,363	1,504,956 1.35%	111,951,445 100.00%	0 0.00%	111,363	Carried
7 Ratification of Prior Issue of 26,766,668 CDIs under ASX Listing Rule 7.4	P	46,885,231	44,913,628 95.79%	471,647 1.01%	595,781	1,499,956 3.20%	46,483,584 99.00%	471,647 1.00%	595,781	Carried
8 Ratification of Prior Issue of 433,332 CDIs under ASX Listing Rule 7.4	P	103,707,661	101,736,058 98.10%	471,647 0.45%	595,781	1,499,956 1.45%	104,026,014 99.55%	471,647 0.45%	595,781	Carried



Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)			Results
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
9 Ratification of Prior Issue of 7,300,000 Broker Options under ASX Listing Rule 7.4	P	47,106,864	45,117,280 95.78%	489,628 1.04%	8,265,114	1,499,956 3.18%	46,687,236 98.96%	489,628 1.04%	8,985,114	Carried
10 Approval of Issue of CDIs to Mr. John Moore, Chair and Director of the Company	P	103,670,634	94,242,726 90.91%	7,922,952 7.64%	7,602,174	1,504,956 1.45%	96,537,682 92.42%	7,922,952 7.58%	7,602,174	Carried
11 Approval of Issue of CDIs to Mr. Marcus Frampton, Director of the Company	P	108,291,650	98,863,742 91.29%	7,922,952 7.32%	2,981,158	1,504,956 1.39%	101,158,698 92.74%	7,922,952 7.26%	2,981,158	Carried
12 Approval of Issue of CDIs to Dr. Rüdiger Weseloh, Director of the Company	P	109,960,058	107,748,848 97.99%	706,254 0.64%	1,312,750	1,504,956 1.37%	110,043,804 99.36%	706,254 0.64%	1,312,750	Carried
13 ASX Listing Rule 7.1A Approval of Future Issue of Securities	P	110,713,390	108,893,424 98.36%	310,010 0.28%	559,418	1,509,956 1.36%	111,193,380 99.72%	310,010 0.28%	559,418	Carried
14 Approval of Future Issue of Securities under Equity Incentive Plan	P	87,421,274	84,407,924 96.55%	1,513,394 1.73%	10,910,117	1,499,956 1.72%	86,697,880 98.28%	1,513,394 1.72%	10,910,117	Carried
15 Approval of Issue of Incentive Securities to Mr. John Moore, Chair and Director of the Company	P	87,421,274	77,186,226 88.29%	8,730,092 9.99%	19,191,462	1,504,956 1.72%	79,481,182 90.10%	8,730,092 9.90%	19,191,462	Carried
16 Approval of Issue of Incentive Securities to Mr. Christopher Cox, Director of the Company	P	87,421,274	84,402,924 96.55%	1,513,394 1.73%	13,543,706	1,504,956 1.72%	86,697,880 98.28%	1,513,394 1.72%	13,543,706	Carried
17 Approval of Issue of Incentive Securities to Dr. Ian Dixon, Director of the Company	P	87,242,575	57,605,812 66.03%	27,998,473 32.09%	12,297,405	1,638,290 1.88%	60,034,102 68.20%	27,998,473 31.80%	12,297,405	Carried
18 Approval of Issue of Incentive Securities to Mr. Marcus Frampton, Director of the Company	P	87,421,274	84,224,225 96.34%	1,692,093 1.94%	14,570,446	1,504,956 1.72%	86,519,181 98.08%	1,692,093 1.92%	14,570,446	Carried
19 Approval of Issue of Incentive Securities to Dr. Rüdiger Weseloh, Director of the Company	P	87,421,274	84,402,924 96.55%	1,513,394 1.73%	12,902,038	1,504,956 1.72%	86,697,880 98.28%	1,513,394 1.72%	12,902,038	Carried
20 Approval of Equity Incentive Plan	P	110,738,390	107,725,040 97.28%	1,513,394 1.37%	534,418	1,499,956 1.35%	110,014,996 98.64%	1,513,394 1.36%	534,418	Carried

